Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study

References

• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425suppl 3iii49iii5625210086
   PubMed Web of Science ®Google Scholar
• LjungbergBBensalahKCanfieldSEAU guidelines on renal cell carcinoma: 2014 updateEur Urol201567591392425616710
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology. Kidney Cancer, Version 2.2016 Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdfAccessed July 13, 2016
   Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTECellaDPazopanib versus sunitinib in metastatic renal-cell carcinomaN Engl J Med2013369872273123964934
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• EbleJNSauterGEpsteinJISesterhennIAWorld Health Organization classification of tumoursPathology and Genetics of Tumours on the Urinary System and Male Genital OrgansLyon, FranceInternational Agency for Research on Cancer (IARC) Press; International Academy of Pathology (IAP)2016 Available from: https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/BB7.pdfAccessed July 13, 2016
   Google Scholar
• SankinAHakimiAAHsiehJJMolinaAMMetastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategiesFront Oncol201556725905038
   PubMed Web of Science ®Google Scholar
• NickersonMLJaegerEShiYImproved identification of Von Hippel-Lindau gene alterations in clear cell renal tumorsClin Cancer Res200814154726473418676741
   PubMed Web of Science ®Google Scholar
• KaelinWGJrTreatment of kidney cancer: insights provided by the VHL tumor-suppressor proteinCancer200911510 suppl2262227219402056
   PubMedGoogle Scholar
• AaproMSKöhneCHCohenHJExtermannMNever too old? Age should not be a barrier to enrollment in cancer clinical trialsOncologist200510319820415793223
   PubMed Web of Science ®Google Scholar
• HengDYChoueiriTKRiniBIOutcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trialsAnn Oncol201425114915424356626
   PubMed Web of Science ®Google Scholar
• HengDYCChiKNMurrayNA population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerCancer2009115477678319127560
   PubMed Web of Science ®Google Scholar
• ShekDTomlinsonBBrownMBrunsonAPanC-XLaraPNJrEpidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patientsClin Genitourin Cancer2012102939822382008
   PubMed Web of Science ®Google Scholar
• VaishampayanUNVankayalaHVigneauFDThe effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry databaseClin Genitourin Cancer201412212412924225251
   PubMed Web of Science ®Google Scholar
• WahlgrenTHarmenbergUSandströmPTreatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)Br J Cancer201310871541154923531701
   PubMed Web of Science ®Google Scholar
• SoerensenAVDonskovFHermannGGImproved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) Study-2Eur J Cancer201450355356224215846
   PubMed Web of Science ®Google Scholar
• RahimiABorganEAagnesBMøllerBCancer Survival by County and Health Region in Norway, 2000–2009OsloCancer Registry of Norway2016 Available from: https://www.kreftregisteret.no/globalassets/cancer_survival_by_county_and_health_region_in_norway_2000-2009.pdfAccessed July 13, 2016
   Google Scholar
• LarsenIKSmåstuenMJohannesenTBData quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timelinessEur J Cancer20094571218123119091545
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health [homepage on the Internet]Norwegian Prescription DatabaseOslo, NorwayNorwegian Institute of Public Health (NIPH)2016 Available from: http://www.norpd.no/Accessed July 13, 2016
   Google Scholar
• FuruKEstablishment of the nationwide Norwegian prescription database (NorPD) – new opportunities for research in pharmacoepidemiology in NorwayNor Epidemiol2008182129136
   Google Scholar
• Norwegian Government Minister of Health and Care Services [web-page on the Internet]Act of 18 May 2001 No 24 on Personal Health Data Filing Systems and the Processing of Personal Health Data (Personal Health Data Filing System Act)2006 Available from: https://www.regjeringen.no/en/topics/health-and-care/public-health/Act-of-18-May-2001-No-24-on-Personal-Health-Data-Filing-Systems-and-the-Processing-of-Personal-Health-Data-Personal-Health-Data-Filing-System-Act-/id224129/Accessed November 9, 2016
   Google Scholar
• AronMNguyenMMSteinRJGillISImpact of gender in renal cell carcinoma: an analysis of the SEER databaseEur Urol200854113314018160207
   PubMed Web of Science ®Google Scholar
• LiPWongYNArmstrongKSurvival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy erasCancer Med20165216918126645975
   PubMed Web of Science ®Google Scholar
• LindskogMWahlgrenTSandinROverall survival (OS) in Swedish RCC patients treated 2000–2012: update of the RENCOMP studyJ Clin Oncol2015337 suppl Abstr 413
   Google Scholar
• HutsonTEBukowskiRMRiniBIEfficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaBr J Cancer201411051125113224434434
   PubMed Web of Science ®Google Scholar
• KhambatiHKChoueiriTKKollmannsbergerCKEfficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient populationClin Genitourin Cancer201412535435824819320
   PubMed Web of Science ®Google Scholar
• PortaCCalvoEClimentMAEfficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trialEur Urol201261482683322297244
   PubMed Web of Science ®Google Scholar
• ZanardiEGrassiPCavoATreatment of elderly patients with metastatic renal cell carcinomaExpert Rev Anticancer Ther201616332333426654225
   PubMed Web of Science ®Google Scholar
• ProcopioGBellmuntJDutcherJSorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisBr J Cancer2013108231131823322192
   PubMed Web of Science ®Google Scholar
• KohYLimHYAhnJHPhase II trial of everolimus for the treatment of nonclear-cell renal cell carcinomaAnn Oncol20132441026103123180114
   PubMed Web of Science ®Google Scholar
• KroegerNXieWLeeJ-LMetastatic non clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteriaCancer2013119162999300623696129
   PubMed Web of Science ®Google Scholar
• HutsonTNosovDTomczakPTivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902)J Clin Oncol20153315 suppl Abstr 4557
   Google Scholar
• ValletSPahernikSHöfnerTEfficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer centerClin Genitourin Cancer2015133e145e15225596830
   PubMedGoogle Scholar
• KoJJChoueiriTKRiniBIFirst-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCBr J Cancer201411081917192224691425
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol200927345794579919826129
   PubMed Web of Science ®Google Scholar